The Full Wiki

More info on Carbinoxamine

Carbinoxamine: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Carbinoxamine
Systematic (IUPAC) name
2-[(4-chlorophenyl)-pyridin-2-yl-methoxy]-N,N-
dimethyl-ethanamine
Identifiers
CAS number 486-16-8
ATC code R06AA08
PubChem 2564
DrugBank APRD00765
ChemSpider 2466
Chemical data
Formula C16H19ClN2O 
Mol. mass 290.788 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Half life 10 to 20 hours
Therapeutic considerations
Pregnancy cat. C
Legal status 4 mg is FDA approved
Routes Oral: 4 mg tablet or 4 mg/5 mL liquid
 Yes check.svgY(what is this?)  (verify)

Carbinoxamine (Clistin, Palgic) antihistamine and anticholinergic. It was first launched in the United States by the McNeil Corporation under the brand name Clistin. It is now available under the brand name Palgic as 4 mg tablets or 4 mg/5 mL liquid. It is approved by the U.S. Food and Drug Administration (FDA) (specifically at the 4 mg dose/strength) for hay fever (a.k.a. allergic rhinitis, SAR and PAR); vasomotor rhinitis; mild urticaria; angioedema, dermatographism and allergic conjunctivitis.

In June 2006 the FDA announced that more than 120 branded pharmacy products containing carbinoxamine were being illegally marketed, and demanded they be removed from the marketplace. This action was precipitated by twenty-one reported deaths in children under the age of two who had been administered carbinoxamine-containing products. Despite the fact that the drug had not been studied in this age group, a multitude of OTC preparations containing carbinoxamine were being marketed for infants and toddlers. At present, all carbinoxamine-containing formulations are approved only for adults or children ages 3 or older. [1]

References

External links

Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message